{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"4.9","value":"2.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"5.6","value":"1.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"97"}],"units":"Participants"}],"description":"ORR is defined as the proportion of patients with best overall response (BOR) of complete response (CR) or partial response (PR), according to central evaluation and as per modified RECIST 1.0.\n\nCR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received everolimus 10 mg once daily BSC throughout the study","id":"OG000","title":"Everolimus + BSC"},{"description":"Participants received matching placebo once daily plus BSC during the blinded period. Participants were allowed to crossover to treatment with everolimus 10mg once daily plus BSC during the open-label period","id":"OG001","title":"Placebo + BSC"}],"paramType":"NUMBER","populationDescription":"The full analysis set (FAS) consists of all randomized patients. Following the intent-to-treat principle, patients were analyzed according to the treatment arm and stratification factors they were assigned to at randomization.","reportingStatus":"POSTED","timeFrame":"From randomization until end of treatment, assessed up to approximately 2.5 years","title":"Overall Response Rate (ORR) as Per Modified RECIST 1.0 According to Central Evaluation","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}